264 related articles for article (PubMed ID: 14515058)
21. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.
Elens L; Nieuweboer A; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; Mathijssen RH; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(2):137-49. PubMed ID: 23327575
[TBL] [Abstract][Full Text] [Related]
22. Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.
Vanhove T; de Jonge H; de Loor H; Annaert P; Diczfalusy U; Kuypers DR
Br J Clin Pharmacol; 2016 Dec; 82(6):1539-1549. PubMed ID: 27501475
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
24. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
25. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
26. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
27. The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.
Lee SJ; Lee SS; Jeong HE; Shon JH; Ryu JY; Sunwoo YE; Liu KH; Kang W; Park YJ; Shin CM; Shin JG
Drug Metab Dispos; 2007 Nov; 35(11):2095-101. PubMed ID: 17724065
[TBL] [Abstract][Full Text] [Related]
28. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
[TBL] [Abstract][Full Text] [Related]
29. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
30. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
31. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.
Flores-Pérez C; Castillejos-López MJ; Chávez-Pacheco JL; Dávila-Borja VM; Flores-Pérez J; Zárate-Castañón P; Acosta-Bastidas M; Cruz-Escobar J; Torres-Espíndola LM
J Clin Pharm Ther; 2021 Jun; 46(3):633-639. PubMed ID: 33638195
[TBL] [Abstract][Full Text] [Related]
32. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.
Elens L; Nieuweboer AJ; Clarke SJ; Charles KA; de Graan AJ; Haufroid V; van Gelder T; Mathijssen RH; van Schaik RH
Pharmacogenet Genomics; 2013 Mar; 23(3):148-55. PubMed ID: 23324807
[TBL] [Abstract][Full Text] [Related]
33. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.
Yates CR; Zhang W; Song P; Li S; Gaber AO; Kotb M; Honaker MR; Alloway RR; Meibohm B
J Clin Pharmacol; 2003 Jun; 43(6):555-64. PubMed ID: 12817518
[TBL] [Abstract][Full Text] [Related]
34. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
35. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
36. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
[TBL] [Abstract][Full Text] [Related]
37. Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
Thummel KE
Pharmacogenetics; 2003 Oct; 13(10):585-7. PubMed ID: 14515056
[No Abstract] [Full Text] [Related]
38. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
39. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.
Roberts PJ; Rollins KD; Kashuba AD; Paine MF; Nelsen AC; Williams EE; Moran C; Lamba JK; Schuetz EG; Hawke RL
Drug Metab Dispos; 2008 Aug; 36(8):1465-9. PubMed ID: 18490434
[TBL] [Abstract][Full Text] [Related]
40. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
Lown KS; Kolars JC; Thummel KE; Barnett JL; Kunze KL; Wrighton SA; Watkins PB
Drug Metab Dispos; 1994; 22(6):947-55. PubMed ID: 7895614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]